Empirica Therapeutics

Hamilton, Canada Founded: 2018 • Age: 8 yrs Acquired By Century Therapeutics
T-cell therapeutics are developed for brain cancer treatment.

About Empirica Therapeutics

Empirica Therapeutics is a company based in Hamilton (Canada) founded in 2018 by Jason Moffat was acquired by Century Therapeutics in June 2020.. Empirica Therapeutics operates in a competitive market with competitors including Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech, among others.

  • Headquarter Hamilton, Canada
  • Founders Jason Moffat
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Empirica Therapeutics

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Empirica Therapeutics

Empirica Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Century Therapeutics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Developer of adult stem cells to develop therapies for cancer
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Empirica Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Empirica Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Empirica Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Empirica Therapeutics

Empirica Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Imvax, GT Medical Technologies, Basilea, Laminar Pharma and SOM Biotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Patient-specific cell vaccines for glioma treatment are developed.
domain founded_year HQ Location
Medical devices for brain tumor radiation therapy are provided.
domain founded_year HQ Location
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
domain founded_year HQ Location
Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments.
domain founded_year HQ Location
Developer of platform for screening compounds to treat rare diseases
domain founded_year HQ Location
Therapeutic drugs for cancer, eye, and infectious diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Empirica Therapeutics

Frequently Asked Questions about Empirica Therapeutics

When was Empirica Therapeutics founded?

Empirica Therapeutics was founded in 2018.

Where is Empirica Therapeutics located?

Empirica Therapeutics is headquartered in Hamilton, Canada. It is registered at Hamilton, Ontario, Canada.

Who is the current CEO of Empirica Therapeutics?

Sheila Singh is the current CEO of Empirica Therapeutics.

What does Empirica Therapeutics do?

Empirica Therapeutics was founded in 2018 and is based in Hamilton, Canada. T-cell based therapeutics are developed by the company for brain cancer treatment within the biotechnology sector. Operations focus on genetically engineered T cells equipped with chimeric antigen receptors that target the CD133 antigen to identify and eliminate cancer cells. The lead product, eCAR-133, is advanced through preclinical and clinical stages to address unmet needs in oncology.

Who are the top competitors of Empirica Therapeutics?

Empirica Therapeutics's top competitors include Imvax, GT Medical Technologies and Basilea.

Who are Empirica Therapeutics's investors?

Empirica Therapeutics has 1 investor. Key investors include Century Therapeutics.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available